Physician profile

Mark S Ransom

Anesthesiology · San Diego, CA

NPI 1770596033

$1,515.47

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$537.33
Food and Beverage$214.82

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Pacira Pharmaceuticals Incorporated $754.65 2019-2023 Iovera, Exparel, Zilretta
Myoscience INC. $219.19 2019
Stryker Corporation $203.50 2022-2023 Mako
Acelrx Pharmaceuticals, INC. $140.54 2019
Chiesi USA, INC. $135.04 2019
Heron Therapeutics, INC. $24.83 2021
Ferring Pharmaceuticals INC. $22.93 2024 Menopur
Ethicon US, LLC $14.79 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark S Ransom

$1,515.47

in general payments reported 2019-2025

Years
2019-2024
Top company
Pacira Pharmaceuticals Incorporated

https://glasscript.com/doctor/352373/mark-s-ransom

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.